O
STRO icon

OrbiMed’s Sutro Biopharma STRO Stock Holding History

OrbiMed’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20M Buy
+801,144
New +$14.5M 0.4% 57
2021
Q3 		– Sell
-43,370
Closed -$8.06M – 185
2021
Q2 		$8.06M Buy
43,370
+8,370
+24% +$1.64M 0.08% 135
2021
Q1 		$7.97M Hold
35,000
– – 0.07% 129
2020
Q4 		$7.6M Buy
+35,000
New +$5.79M 0.07% 131
2020
Q2 		– Sell
-10,480
Closed -$1.07M – 155
2020
Q1 		$1.07M Hold
10,480
– – 0.02% 132
2019
Q4 		$1.15M Buy
+10,480
New +$1.08M 0.02% 128

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

OrbiMed's STRO Position: Q1 2026 in Review

OrbiMed opened a new position in Sutro Biopharma (STRO) in Q1 2026: 801,144 shares worth $20M. The stake represents 0.4% of the portfolio and ranks #57 among its holdings. This is a return to the name: OrbiMed previously reported a position in STRO as recently as Q2 2021.

OrbiMed first reported a position in STRO in Q4 2019 and has held it in 6 quarters since. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • OrbiMed held 801,144 shares of Sutro Biopharma worth $20M as of Q1 2026.
  • Sutro Biopharma was a new OrbiMed position in Q1 2026.
  • Sutro Biopharma made up 0.4% of OrbiMed's portfolio in Q1 2026, its #57 holding.
  • OrbiMed first reported a position in Sutro Biopharma in Q4 2019 and has held it in 6 quarters since.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.